The Motley Fool
14 Nov 2026, 09:44 UTC · 2d ago
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Impact · against what's priced in
The article provides no actionable catalyst for either company, as the dividend characteristics of both Pfizer and AbbVie are well-understood by the market. AbbVie's Dividend King status is already a core part of its valuation, and Pfizer's high yield is offset by known cash flow pressures.
- ABBV+0.00
Already priced in
- The price assumes
AbbVie has increased its dividend for 53 consecutive years





